Cyclacel Pharmaceuticals has posted new, primary endpoint data from an ongoing, open-label, multicenter, randomized Phase II trial of oral sapacitabine capsules, the company’s lead product candidate, in older patients with myelodysplastic syndromes (MDS) after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine.   The seven-day dose regimen of 200 mg twice daily (Arm G), appears to be a better schedule with a one-year survival rate of 38%, medi...